1. Home
  2. UPLD vs KPRX Comparison

UPLD vs KPRX Comparison

Compare UPLD & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upland Software Inc.

UPLD

Upland Software Inc.

HOLD

Current Price

$4.88

Market Cap

12.8M

Sector

Technology

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$2.66

Market Cap

11.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UPLD
KPRX
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
11.7M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
UPLD
KPRX
Price
$4.88
$2.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$3.75
$10.00
AVG Volume (30 Days)
29.5K
18.4K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
63.38
N/A
EPS
N/A
N/A
Revenue
$74,767,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.95
N/A
52 Week Low
$0.50
$1.76
52 Week High
$6.65
$2.95

Technical Indicators

Market Signals
Indicator
UPLD
KPRX
Relative Strength Index (RSI) 50.92 52.39
Support Level $4.01 $2.44
Resistance Level $5.65 $2.61
Average True Range (ATR) 0.67 0.10
MACD -0.08 0.00
Stochastic Oscillator 30.16 69.23

Price Performance

Historical Comparison
UPLD
KPRX

About UPLD Upland Software Inc.

Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: